The effects of celecoxib augmentation on cytokine levels in schizophrenia
Open Access
- 22 July 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 9 (3) , 343-348
Abstract
Celecoxib augmentation therapy has been reported to enhance the rate of clinical response for patients with schizophrenia. This may be due in part to an effect of celecoxib in the immune dysfunction associated with schizophrenia. Given concerns about the safety of COX-2 inhibitors, studies investigating cytokine levels in medicated patients with schizophrenia are of public health importance. Twenty-eight schizophrenia subjects stabilized on olanzapine or risperidone were randomized to receive 8 wk of celecoxib (400 mg/d) or placebo. Serum soluble IL-2 receptor (sIL-2r) and in-vitro PHA-stimulated whole-blood cytokine production levels were measured at baseline, 1 wk, and 8 wk. Celecoxib augmentation did not alter any of the cytokine parameters measured for the overall study group. However, 1 wk of celecoxib augmentation increased TNF-α and IL-2 production levels in olanzapine-treated subjects. These elevations did not persist by week 8. Overall, celecoxib does not significantly modify cytokine levels in medicated schizophrenia subjects.Keywords
This publication has 17 references indexed in Scilit:
- Celecoxib Augmentation of Continuously Ill Patients with SchizophreniaBiological Psychiatry, 2005
- COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapyEuropean Archives of Psychiatry and Clinical Neuroscience, 2004
- Beneficial Antipsychotic Effects of Celecoxib Add-On Therapy Compared to Risperidone Alone in SchizophreniaAmerican Journal of Psychiatry, 2002
- In Vitro Cytokine Secretion in Individuals with Schizophrenia: Results, Confounding Factors, and Implications for Further ResearchBrain, Behavior, and Immunity, 2001
- An Abbreviated Review of Immune Abnormalities in SchizophreniaCNS Spectrums, 2001
- Drug metabolism and atypical antipsychoticsEuropean Neuropsychopharmacology, 1999
- Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjectsProstaglandins, Leukotrienes and Essential Fatty Acids, 1998
- Short and long term immunosuppressive effects of clozapine and haloperidolImmunopharmacology, 1997
- Cytokine production in drug-free and neuroleptic-treated schizophrenic patientsBiological Psychiatry, 1995
- Pharmacology of the pyrroloimidazole, SK&F 105809—I: Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acidBiochemical Pharmacology, 1991